Biologic and biochemical analyses of p16(INK4a) mutations from primary tumors

Journal of the National Cancer Institute

Volumn 91, Issue 18, 1999, Pages 1569-1574

  Yarbrough, Wendell G ^a,b   Buckmire, Robert A ^a   Bessho, Mika ^b   Liu, Edison T ^c  

^a UNIVERSITY OF NORTH CAROLINA SCHOOL OF MEDICINE   (United States)

^b UNIVERSITY OF NORTH CAROLINA   (United States)

^c NATIONAL CANCER INSTITUTE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CYCLIN DEPENDENT KINASE; MUTANT PROTEIN; PROTEIN P16;

ARTICLE; CARCINOGENESIS; CELL CYCLE; ENZYME BINDING; ENZYME INHIBITION; GENE MUTATION; HUMAN; IMMUNOPRECIPITATION; MISSENSE MUTATION; NUCLEOTIDE SEQUENCE; POINT MUTATION; PRIORITY JOURNAL; TUMOR SUPPRESSOR GENE;

EID: 0033568342     PISSN: 00278874     EISSN: None     Source Type: Journal    
DOI: 10.1093/jnci/91.18.1569     Document Type: Article

References (23)

1. Weinberg RA. The retinoblastoma protein and cell cycle control. Cell 1995;81:323-30.
2. Cairns P, Polascik TJ, Eby Y, Tokino K, Califano J, Merlo A, et al. Frequency of homozygous deletion at p16/CDKN2 in primary human tumours. Nat Genet 1995;11:210-2.
3. Herman JG, Merlo A, Mao L, Lapidus RG, Issa JP, Davidson NE, et al. Inactivation of the CDKN2/p16/MTSI gene is frequently associated with aberrant DNA methylation in all common human cancers. Cancer Res 1995;55: 4525-30.
4. Ranade K, Hussussian CJ, Sikorski RS, Varmus HE, Goldstein AM, Tucker MA, et al. Mutations associated with familial melanoma impair p16INK4 function [letter]. Nat Genet 1995;10:114-6.
5. Koh J, Enders GH, Dynlacht BD, Harlow E. Tumour-derived p16 alleles encoding proteins defective in cell-cycle inhibition. Nature 1995; 375:506-10.
6. Goldstein AM, Fraser MC, Struewing JP, Hussussian CJ, Ranade K, Zametkin DP, et al. Increased risk of pancreatic cancer in melanomaprone kindreds with p16INK4 mutations. N Engl J Med 1995;333:970-4.
7. Yarbrough WG, Aprelikova O, Pei H, Olshan AF, Liu ET. Familial tumor syndrome associated with a germline nonfunctional p16INK4a allele. J Natl Cancer Inst 1996;88:1489-91.
8. Tevelev A, Byeon IJ, Selby T, Ericson K, Kim HJ, Kraynov V, et al. Tumor suppressor p6INK4A: structural characterization of wild-type and mutant proteins by NMR and circular dichroism. Biochemistry 1996;35:9475-87.
9. Byeon IJ, Li J, Ericson K, Selby TL, Tevelev A, Kim HJ, et al. Tumor suppressor p16INK4A: determination of solution structure and analyses of its interaction with cyclin-dependenl kinase 4. Mol Cell 1998;1:421-31.
10. Pollock PM, Pearson JV, Hayward NK. Compilation of somatic mutations of the CDKN2 gene in human cancers: non-random distribution of base substitutions. Genes Chromosomes Cancer 1996;5:77-88.
11. Lukas J, Parry D, Aagaard L, Mann DJ, Bartkova J, Strauss M, et al. Retinoblastoma-protein-dependent cell-cycle inhibition by the tumour suppressor p16. Nature 1995;375: 503-6.
12. Reymond A, Brent R. p16 proteins from melanoma-prone families are deficient in binding to Cdk4. Oncogene 1995;11:1173-8.
13. Yang R, Gombart AF, Serrano M, Koeffler HP. Mutational effects on the p16INK4a tumor suppressor protein. Cancer Res 1995;55: 2503-6.
14. Quelle DE, Cheng M, Ashmun RA, Sherr CJ. Cancer-associated mutations at the INK4a locus cancel cell cycle arrest by p161NK4a but not by the alternative reading frame protein p19ARF. Proc Natl Acad Sci USA 1997;94: 669-73.
15. Yoshida S, Todoroki T, Ichikawa Y, Hanai S, Suzuki H, Hori M, et al. Mutations of p16Ink4/CDKN2 and p15Ink4B/MTS2 genes in biliary tract cancers. Cancer Res 1995;55:2756-60.
16. Zhang SY, Klein-Szanto AJ, Sauter ER, Shafarenko M, Mitsunaga S, Nobori T, et al. Higher frequency of alterations in the p16/CDKN2 gene in squamous cell carcinoma cell lines than in primary tumors of the head and neck. Cancer Res 1994;54:5050-3.
17. Mori T, Miura K, Aoki T, Nishihira T, Mori S, Nakamura Y. Frequent somatic mutation of the MTS1/CDK4I (multiple tumor suppressor/cyclin-dependent kinase 4 inhibitor) gene in esophageal squamous cell carcinoma. Cancer Res 1994;54:3396-7.
18. Hussussian CJ, Struewing JP, Goldstein AM, Higgins PA, Ally DS, Sheahan MD, et al. Germline p16 mutations in familial melanoma. Nat Genet 1994;8:15-21.
19. Sanger F, Nicklen S, Coulson AR. DNA sequencing with chain-terminating inhibitors. Proc Natl Acad Sci U S A 1977;74:5463-7.
20. Craven RJ, Cance WG, Liu ET. The nuclear tyrosine kinase rak associates with the retinoblastoma protein pRb. Cancer Res 1995;55: 3969-72.
21. Aprelikova O, Xiong Y, Liu ET. Both p16 and p21 families of cyclin-dependent kinase (CDK) inhibitors block the phosphorylation of cyclin-dependent kinases by the CDK-activating kinase. J Biol Chem 1995;270:18195-7.
22. van den Heuvel S, Harlow E. Distinct roles for cyclin-dependent kinases in cell cycle control. Science 1993;262:2050-4.
23. CDKN2 associated with familial melanoma. Mol Cell Biol 1996;16:3844-52.